Skip to main content
SpringerLink
Log in

Immunoprophylaxis of Hepatitis B Virus Infection and Its Sequelae

  • Chapter
Hepatitis B Virus in Human Diseases

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 2020 Accesses

Abstract

Hepatitis B virus (HBV) infection is a major global health problem. It can cause acute, fulminant, or chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Primary prevention through immunization is the best way to control HBV infection and its complication. Infantile immunization with hepatitis B vaccine starting at birth is the best way to achieve high protective efficacy. HBIG at birth can increase the prevention efficacy.

After the lunch of hepatitis B immunization program in infancy, the incidences of acute, fulminant, and chronic hepatitis B were reduced. Significant reduction of HCC incidences in children and adolescents by universal HBV immunization supports HBV vaccine as the first successful cancer preventive vaccine in human.

In spite of the great success, breakthrough HBV infection in spite of complete immunization in infants of highly infectious mothers, immune compromised host with poor response to HBV vaccination, and low vaccine coverage rate in areas with inadequate resources are problems to be solved. Further efforts to overcome those difficulties are needed to achieve the goal of eradication of HBV infection and its sequelae.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.

    Article  CAS  PubMed  Google Scholar 

  2. Theise ND. Liver cancer. In: Stewart BW, Wild CP, editors. World cancer report 2014. Lyon, France: IARC, WHO press; 2014.

    Google Scholar 

  3. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:s294–308.

    Article  CAS  PubMed  Google Scholar 

  4. Vardas E, Mathai M, Blaauw D, et al. Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol. 1999;58:111–5.

    Article  CAS  PubMed  Google Scholar 

  5. Sangare L, Sombie R, Combassere AW, et al. Antenatal transmission of hepatitis B virus in an area of HIV moderate prevalence, Burkina Faso. Bull Soc Pathol Exot. 2009;102:226–9.

    CAS  PubMed  Google Scholar 

  6. Howell J, Lemoine M, Thursz M. Prevention of materno-foetal transmission of hepatitis in sub-Saharan Africa: the evidence, current practice and future challenges. J Viral Hepat. 2014;21:381–96.

    Article  CAS  PubMed  Google Scholar 

  7. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771–4.

    Article  CAS  PubMed  Google Scholar 

  8. Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis. 1982;146:198–204.

    Article  CAS  PubMed  Google Scholar 

  9. Beasley RP, Hwang LY, Lin CC, Ko YC, Twu SJ. Incidence of hepatitis among students at a university in Taiwan. Am J Epidemiol. 1983;117:213–22.

    CAS  PubMed  Google Scholar 

  10. Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr. 1998;133:374–7.

    Article  CAS  PubMed  Google Scholar 

  11. Lin HH, Lee TY, Chen DS, et al. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr. 1987;111:877–81.

    Article  CAS  PubMed  Google Scholar 

  12. Shiraki K, Yoshihara N, Sakurai M, et al. Acute hepatitis B in infants born to carrier mother with the antibody to hepatitis B e antigen. J Pediatr. 1980;97:768–70.

    Article  CAS  PubMed  Google Scholar 

  13. Chang MH, Lee CY, Chen DS, Hsu HC, Lai MY. Fulminant hepatitis in children in Taiwan: the important role of hepatitis B virus. J Pediatr. 1987;111:34–9.

    Article  CAS  PubMed  Google Scholar 

  14. Beasley RP, Hwang LY, Stevens CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983;3:135–41.

    Article  CAS  PubMed  Google Scholar 

  15. Hilleman MR. Overview of the needs and realities for developing new and improved vaccines in the 21st century. Intervirology. 2002;45:199–211.

    Article  CAS  PubMed  Google Scholar 

  16. Buynak EB, Roehm RR, Tytell AA, et al. Vaccine against human hepatitis B. JAMA. 1976;235:2832–4.

    Article  CAS  PubMed  Google Scholar 

  17. Maupas P, Chiron JP, Barin F, et al. Efficacy of hepatitis B vaccine in prevention of earl HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet. 1981;1:289–92.

    Article  CAS  PubMed  Google Scholar 

  18. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 1982;298:347–50.

    Article  CAS  PubMed  Google Scholar 

  19. Hilleman MR. Yeast recombinant hepatitis B vaccine. Infection. 1987;15:3–7.

    Article  CAS  PubMed  Google Scholar 

  20. Lee GC, Hwang LY, Beasley RP, Chen SH, Lee TY. Immunogenicity of hepatitis B virus vaccine in healthy Chinese neonates. J Infect Dis. 1983;148:526–9.

    Article  CAS  PubMed  Google Scholar 

  21. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2:1099–102.

    Article  CAS  PubMed  Google Scholar 

  22. Lo KJ, Tsai YT, Lee SD, et al. Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology. 1985;32:65–8.

    CAS  PubMed  Google Scholar 

  23. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA. 1987;257:2612–6.

    Article  CAS  PubMed  Google Scholar 

  24. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54:1–31.

    PubMed  Google Scholar 

  25. Bonanni P. Implementation in Italy of a universal vaccination programme against hepatitis B. Vaccine. 1995;13 Suppl 1:S68–71.

    Article  PubMed  Google Scholar 

  26. Vimolket T, Poovorawan Y. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness. Southeast Asian J Trop Med Public Health. 2005;36:693–9.

    PubMed  Google Scholar 

  27. Chen DS, Hsu NHM, Sung JL, et al. The Hepatitis Steering Committee, The Hepatitis Control Committee: A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen carrier-mothers. JAMA. 1987;257:2597–603.

    Article  CAS  PubMed  Google Scholar 

  28. Chongsrisawat V, Yoocharoen P, Theamboonlers A, et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health. 2006;11:1496–502.

    Article  PubMed  Google Scholar 

  29. Chang MH. Prevention of hepatitis B virus infection and liver cancer. Recent Results Cancer Res. 2014;193:75–95.

    Article  CAS  PubMed  Google Scholar 

  30. Lavanchy D. Viral hepatitis: global goals for vaccination. J Clin Virol. 2012;55:296–302.

    Article  PubMed  Google Scholar 

  31. Wasley A, Miller JT, Finelli L, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis—United States, 2005. MMWR Surv Summ. 2007;56:1–24.

    Google Scholar 

  32. Su WJ, Liu CC, Liu DP, et al. Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. J Infect Dis. 2012;205:757–62.

    Article  PubMed  Google Scholar 

  33. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr. 2001;139:349–52.

    Article  CAS  PubMed  Google Scholar 

  34. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the National Hepatitis B Immunization Program in Taiwan. JAMA. 2013;310:974–6.

    Article  CAS  PubMed  Google Scholar 

  35. Chen HL, Chang CJ, Kong MS, et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology. 2004;39:58–63.

    Article  PubMed  Google Scholar 

  36. Hsu HM, Chen DS, Chuang CH, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan: studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA. 1988;260:2231–5.

    Article  CAS  PubMed  Google Scholar 

  37. Chen ST, Chang MH. Epidemiology and natural history of hepatitis B in children. In: Jonas M, editor. Viral hepatitis in children. New York: Humana Press; 2010. p. 13–28.

    Chapter  Google Scholar 

  38. Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol. 1986;18:301–7.

    Article  CAS  PubMed  Google Scholar 

  39. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA. 1996;276:906–8.

    Article  CAS  PubMed  Google Scholar 

  40. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135:796–800.

    Article  CAS  PubMed  Google Scholar 

  41. Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology. 2007;132:1287–93.

    Article  PubMed  Google Scholar 

  42. Ni YH, Chang MH, Wu JF, et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol. 2012;57:730–5.

    Article  PubMed  Google Scholar 

  43. Whittle HC, Maine N, Pilkington J, et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet. 1995;345:1089–92.

    Article  CAS  PubMed  Google Scholar 

  44. Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunisation program. BMC Infect Dis. 2014;14:7.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Chang MH, Chen DS, Hsu HC, et al. Maternal transmission of hepatitis B virus in childhood HCC. Cancer. 1989;64:2377–80.

    Article  CAS  PubMed  Google Scholar 

  46. Chang MH, Chen PJ, Chen JY, et al. Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. Hepatology. 1991;13:316–20.

    Article  CAS  PubMed  Google Scholar 

  47. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336:1855–9.

    Article  CAS  PubMed  Google Scholar 

  48. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101:1348–55.

    Article  CAS  PubMed  Google Scholar 

  49. Wichajarn K, Kosalaraksa P, Wiangnon S. Incidence of HCC in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev. 2008;9:507–9.

    PubMed  Google Scholar 

  50. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011;54:801–7.

    Article  PubMed  Google Scholar 

  51. Chien YC, Jan CF, Chiang CJ, et al. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees. Hepatology. 2014;60:125–32.

    Article  CAS  PubMed  Google Scholar 

  52. Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet. 1991;338:1174–5.

    Article  CAS  PubMed  Google Scholar 

  53. Martínez-Sernández V, Figueiras A. Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production. J Neurol. 2013;260:1951–9.

    Article  PubMed  Google Scholar 

  54. van Herck K, Vorsters A, Van Damme P. Prevention of viral hepatitis (B and C) reassessed. Best Pract Res Clin Gastroenterol. 2008;22:1009–29.

    Article  PubMed  Google Scholar 

  55. Wen WH, Chang MH, Zhao LL, Ni YH, Hsu HY, Wu JF, Chen PJ, Chen DS, Chen HL. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol. 2013;59:24–30.

    Article  PubMed  Google Scholar 

  56. Chen HL, Lin LH, Hu FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142:773–81.

    Article  PubMed  Google Scholar 

  57. Hsu HY, Chang MH, Ni YH, et al. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis. 2010;201:1192–200.

    Article  PubMed  Google Scholar 

  58. Hsu HY, Chang MH, Ni YH, et al. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant. J Infect Dis. 2013;207:1047–57.

    Article  CAS  PubMed  Google Scholar 

  59. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J Exp Med. 1992;175:495–502.

    Article  CAS  PubMed  Google Scholar 

  60. van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003;10:294–7.

    Article  PubMed  Google Scholar 

  61. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94–103.

    Article  PubMed  Google Scholar 

  62. Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215–21.

    Article  CAS  PubMed  Google Scholar 

  63. Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lmivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60:468–76.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of HBV. J Hepatol. 2014;61:502–7.

    Article  CAS  PubMed  Google Scholar 

  65. Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 2015;62:375-86.

    Google Scholar 

Download references

Acknowledgement

Grant support from National Health Research Institute (NHRI-EX103-10001BI)

Author information

Authors and Affiliations

  1. Department of Pediatrics, and Hepatitis Research Center, National Taiwan University Hospital, No. 8, Chung-Shan S. Road, Taipei, Taiwan

    Mei-Hwei Chang M.D.

Authors
  1. Mei-Hwei Chang M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mei-Hwei Chang M.D. .

Editor information

Editors and Affiliations

  1. Chang Gung University, Chang Gung Memorial Hospital, Taipei, Taiwan

    Yun-Fan Liaw

  2. INSERM Unit 1052, Hospices Civils de Lyon, Lyon University, Lyon, France

    Fabien Zoulim

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Chang, MH. (2016). Immunoprophylaxis of Hepatitis B Virus Infection and Its Sequelae. In: Liaw, YF., Zoulim, F. (eds) Hepatitis B Virus in Human Diseases. Molecular and Translational Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-22330-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22330-8_19

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-22329-2

  • Online ISBN: 978-3-319-22330-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation